Trial Profile

A Phase 1 Study of SGN-CD47M in Patients With Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 28 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SGN CD47M (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors Seagen

Most Recent Events

15 Sep 2020 Status changed from recruiting to discontinued as per According to NCT,as per sponsor decision based on portfolio prioritization..
19 Apr 2020 Planned End Date changed from 1 Mar 2022 to 30 Sep 2022.
19 Apr 2020 Planned primary completion date changed from 1 Sep 2021 to 31 Mar 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com